New drug ALXN2030 put to the test in healthy volunteers
NCT ID NCT05501717
First seen Feb 20, 2026 · Last updated May 25, 2026 · Updated 9 times
Summary
This early-stage study is testing a single dose of a new drug called ALXN2030 in 48 healthy adults. The main goal is to see if it is safe and what side effects it may cause. Researchers will also measure how the drug behaves in the body and how the immune system responds. This is a first step to gather important safety information before testing the drug in people with a disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Harrow, HA1 3UJ, United Kingdom
Conditions
Explore the condition pages connected to this study.